Logo_Axithra

Rapid, cost-effective therapeutic drug monitoring at point of need.

Mission

Axithra’s groundbreaking optics and photonics technology aims to revolutionize bedside therapeutic drug monitoring with its unparalleled speed, cost-effectiveness, and accuracy.

Our mission is to provide healthcare professionals with rapid, clinically actionable results tailored to the individual patient to ensure drug effectiveness, avoid adverse drug reactions, improve patient outcomes, and accelerate advantageous health economics.

Discover more about Axithra

Our technology

Our technology leverages the power of photonics to rapidly and accurately detect and quantify the molecular fingerprints of compounds in patient blood.

Unlike other approaches, we specifically measure the concentration of the active, free fraction of drugs to provide the most reliable and clinically meaningful results for personalized therapeutic drug monitoring. We achieve active drug fraction measurements with our proprietary method, implementing Raman spectroscopy on a chip to enable rapid and accurate tailored dosing adjustments.

Discover our technology

Our technology

Our technology leverages the power of photonics to rapidly and accurately detect and quantify the molecular fingerprints of compounds in patient blood.

Unlike other approaches, we specifically measure the concentration of the active, free fraction of drugs to provide the most reliable and clinically meaningful results for personalized therapeutic drug monitoring. We achieve active drug fraction measurements with our proprietary method, implementing Raman spectroscopy on a chip to enable rapid and accurate tailored dosing adjustments.

Discover our technology

The benefits

Rapid readouts for actionable therapeutic drug monitoring

Accurate measurements of the free drug fraction for personalized dosing

Seamless clinical workflow integration with no sample pre-treatment

Quick and cost-effective with low implementation and usage expenses

Simultaneous quantification of multiple drugs

No biomarker development required

No background interference

Learn more

Applications

The need for rapid therapeutic drug monitoring

Therapeutic drug monitoring leads to better clinical outcomes, reduced drug toxicity, lower mortality, reduced health- care spending, improved antimicrobial stewardship, and better global health.

However, current methods are too slow, expensive, and not scalable enough for effective clinical use at the point of need, where its impact would be greatest.

To deliver maximum impact for patients and clinicians, our current and future application pipelines target the therapeutic drug monitoring of antibiotics, oncology drugs, antifungals, and patient adherence assessment.

Antibiotics

Our lead application focuses on the rapid therapeutic drug monitoring of β-lactam antibiotics in the intensive care setting (ICU). Globally, around seven million patients receive β-lactam antibiotics in ICUs, but patients frequently receive inadequate drug concentrations for their personalized physiology or needs. 1-5
  • 65 – 85% of patients receive incorrect dosage 6,7
  • Active drug fraction varies 10-fold between patients 8
  • Personalized dosing ensures drug effectiveness and reduces adverse reactions 6,7,9-11
  • Therapeutic drug monitoring reduces length of ICU stay by 30% 9
Discover more
Discover more
  1. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clinical infectious diseases. 2014 Apr 15;58(8):1072-83.
  2. Richter DC, Frey O, Röhr A, Roberts JA, Köberer A, Fuchs T, Papadimas N, Heinzel-Gutenbrunner M, Brenner T, Lichtenstern C, Weigand MA. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection. 2019 Dec;47:1001-11.
  3. Wallenburg E, Ter Heine R, de Lange DW, van Leeuwen H, Schouten JA, Ten Oever J, Kolwijck E, Burger DM, Pickkers P, Gieling EM, de Maat MM. High unbound flucloxacillin fraction in critically ill patients. Journal of Antimicrobial Chemotherapy. 2021 Dec 1;76(12):3220-8.
  4. Al-Shaer MH, Rubido E, Cherabuddi K, Venugopalan V, Klinker K, Peloquin C. Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients. Journal of Antimicrobial Chemotherapy. 2020 Dec;75(12):3644-51.
  5. Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al‐Ouqaili MT, Chinedu Ikem J, Victor Chigozie U, Saki M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. Journal of clinical laboratory analysis. 2022 Sep;36(9):e24655.
  6. De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, Leroux-Roels I, Hoste E, Depuydt P, Decruyenaere J, Verstraete AG. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive care medicine. 2014 Mar;40:380-7.
  7. Sime FB, Roberts MS, Tiong IS, Gardner JH, Lehman S, Peake SL, Hahn U, Warner MS, Roberts JA. Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. Journal of Antimicrobial Chemotherapy. 2015 Aug;70(8):2369-75.
  8. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, Finfer S, Pelosi P, Brazzi L, Aditianingsih D, Timsit JF. Prevalence and outcomes of infection among patients in intensive care units in 2017. Jama. 2020 Apr 21;323(15):1478-87.
  9. McLaughlin AM, Hardt J, Canavan JB, Donnelly MB. Determining the economic cost of ICU treatment: a prospective “micro-costing” study. Intensive care medicine. 2009 Dec;35:2135-40.
  10. Commission notice – EU Guidelines for the prudent use of antimicrobials in human health (2017/C 212/01) Available from: https://health.ec.europa.eu/publications/commission-notice-eu-guidelines-prudent-use-antimicrobials-human-health_en
  11. Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. The Lancet Oncology. 2019 Jun 1;20(6):769-80.
  12. Knezevic CE, Clarke W. Cancer chemotherapy: The case for therapeutic drug monitoring. Therapeutic drug monitoring. 2020 Feb 1;42(1):6-19.
  13. Denning DW. Global incidence and mortality of severe fungal disease. The Lancet Infectious Diseases. 2024 Jan 12.
  14. Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, Bromley M, Brüggemann R, Garber G, Cornely OA, Gurr SJ. Tackling the emerging threat of antifungal resistance to human health. Nature reviews microbiology. 2022 Sep;20(9):557-71.
  15. Vena A, Muñoz P, Mateos M, Guinea J, Galar A, Pea F, Alvarez-Uria A, Escribano P, Bouza E. Therapeutic drug monitoring of antifungal drugs: another tool to improve patient outcome? Infectious Diseases and Therapy. 2020 Mar;9:137-49.
  16. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. Journal of Antimicrobial Chemotherapy. 2014 May 1;69(5):1162-76.

Contact us to find out more


Proudly supported by

Learn how we helped 100 top brands gain success